AASLD 2025 Nov 7-11 Wash DC
 
Tilly Varughese1, Man-Fung Yuen2, Grace Lai Hung Wong3, Kosh Agarwal4, Kevin Gray1, Deana Antoniello1, Varun Sharma1, Joanne Brown1, Elina Medvedeva1, Gaston Picchio1, Karen D. Sims1
1 Arbutus Biopharma, Warminster, PA, United States, 2The University of Hong Kong, Queen Mary Hospital, Hong Kong, China, 3Medical Data Analytics Centre, State Key Laboratory of Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China, 4King's College Hospital, London, United Kingdom

AASLD2024: Preliminary Antiviral Efficacy and Safety of Repeat Dosing of Imdusiran (AB-729) Followed by VTP-300 With or Without Nivolumab in Virally-Suppressed, Non-Cirrhotic Subjects With Chronic Hepatitis B (CHB)
 
EASL2024: Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone
 
EASL2023: Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection